Markets:

Overview

News

Currencies

International

Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

16.77 +0.82 (+5.14%)

Official Closing Price Updated: 7:00 PM EDT, Jul 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients ↗

November 14, 2024

AC Immune reports interim results from Phase 2 trial of ACI-7104.056 active immunotherapy for early Parkinson's disease.

Via Benzinga

Urgency, Debate Mark COP29 As Leaders Push For Carbon Market Rules, Worry About Trump ↗

November 12, 2024

Global leaders gather at COP29 to address climate change, carbon market mechanisms, and climate finance. Urgency and controversy at a fossil fuel reliant host country, but focus on establishing rules...

Via Benzinga

Topics Climate Change

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

October 31, 2024

— US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer —

From HUTCHMED (China) Limited

Via GlobeNewswire

Preview: Takeda Pharmaceutical's Earnings ↗

October 30, 2024

Via Benzinga

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

October 31, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem

October 24, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside ↗

October 17, 2024

HC Wainwright has initiated coverage on Alumis, highlighting the biopharmaceutical company's lead drug candidate, ESK-001. The analyst notes ESK-001's superior clinical data compared to Bristol Myers...

Via Benzinga

Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization ↗

October 04, 2024

Johnson & Johnson has discontinued its Phase 2 study of mosnodenvir, an investigational antiviral candidate for dengue prevention, as part of a strategic shift in its R&D portfolio. Final efficacy data...

Via Benzinga

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer

September 24, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

September 24, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut

September 20, 2024

Wave Life Sciences has received recent Wall Street price targets forecasting big upside. The company has a potentially "industry-leading" treatment.

Via MarketBeat

Topics Economy

Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024

September 19, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries

September 18, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines ↗

September 10, 2024

Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in-class lead asset with promising Phase 2 data in rare blood cancer and a multi-billion dollar potential.

Via Benzinga

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst ↗

September 09, 2024

HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant...

Via Benzinga

Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production ↗

September 06, 2024

Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally.

Via Benzinga

Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues ↗

August 12, 2024

FDA grants approval to Ascendis Pharma's Yorvipath (TransCon PTH) for adult hypoparathyroidism. Yorvipath offers continuous parathyroid hormone exposure and is set to launch in the U.S. with patient...

Via Benzinga

New Study Reveals How Classical Music Could Revolutionize Depression Care

August 12, 2024

In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of...

Via PressReach

Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday? ↗

August 07, 2024

Takeda Pharmaceutical stock rises following European Commission approval of Adzynma for treating ADAMTS13 deficiency in cTTP patients. Adzynma is the first enzyme replacement therapy in the EU for this...

Via Benzinga

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

August 07, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q1 2024 ↗

July 31, 2024

Takeda Pharmaceutical just reported results for the first quarter of 2024.

Via InvestorPlace

Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline

July 31, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

3 Biotech Stocks to Buy on the Dip: July 2024 ↗

July 29, 2024

Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip.

Via InvestorPlace

Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation ↗

July 24, 2024

Guggenheim Partners initiated coverage on Alumis, highlighting its lead asset ESK-001, a TYK2 inhibitor for plaque psoriasis and systemic lupus erythematosus. With upcoming Phase 3 trials and no JAK...

Via Benzinga

Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst ↗

July 09, 2024

Eli Lilly's acquisition of Morphic highlights strategic expansion in Immunology, targeting α4β7 for ulcerative colitis and Crohn's disease treatments. Goldman Sachs notes the deal's potential to...

Via Benzinga

Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma ↗

July 06, 2024

Samsung Biologics, a Korean CDMO, signed a $1.06 billion agreement to provide manufacturing services for an unnamed US pharma. The agreement is the largest that Samsung Bio has made since it was...

Via Talk Markets

Blackstone Nears $2.2B Deal For Sale Of Japanese Supplement Maker Alinamin: Report ↗

July 02, 2024

Blackstone Inc. is reportedly finalizing a deal to sell Alinamin Pharmaceutical to MBK Partners for $2.17 billion. Blackstone acquired Alinamin from Takeda in 2020.

Via Benzinga

Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600 ↗

June 28, 2024

Protagonist Therapeutics will join the SmallCap 600 on Wednesday.

Via Investor's Business Daily

Topics Stocks

Takeda Announces New Assignments of Directors

June 26, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

June 24, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.